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Starter packs: a good start to therapy?
Marea P Patounas, Team Leader, Medicines Contact Centre, and Treasure M McGuire, 
Assistant Director of Pharmacy, Mater Misericordiae Health Services, Brisbane
Summary 
Samples of drugs are often given to doctors 
by pharmaceutical representatives as part of a 
marketing strategy. Despite the well described 
advantages of drug samples, little has been 
published on the potential adverse outcomes. A 
series of consumer calls to the Adverse Medicine 
Events Line has highlighted concerns regarding 
the quality use of medicines associated with drug 
samples. The most commonly reported problems 
were drug samples being supplied to patients 
with inadequate information regarding dosage, 
administration, storage and possible adverse effects. 
In addition, some patients were given excessive 
quantities of a drug. To reduce such adverse 
outcomes, the drug industry, health professionals 
and consumers should be aware of the potential 
problems associated with starter packs.
Key words: Adverse Medicine Events Line, consumer information, 
drug industry.
(Aust Prescr 2007;30:14–16)
Introduction
Starter packs are samples of drugs given to doctors by 
pharmaceutical representatives, often as part of a marketing 
strategy. Medicines Australia's Code of Conduct states that 
starter packs are '… a quantity of a product supplied without 
cost to medical practitioners, dentists and 
hospital pharmacists'.1 
The pros and cons of starter 
packs
There are both advantages and 
disadvantages in the provision of starter 
packs. From a manufacturer's perspective, starter packs 
provide an avenue to introduce new or unique products to the 
marketplace. Evidence suggests that drug samples influence 
prescribing behaviour and increase prescribing of a particular 
product.2,3,4,5 Advantages for doctors include being able to 
assess the efficacy or tolerability of new treatments and to 
provide immediate treatment such as antibiotics after hours. 
This is especially beneficial in remote or rural populations. 
Likewise, patients can try a new drug before having to pay for 
a prescription and may be able to access drugs that are not yet 
available on the Pharmaceutical Benefits Scheme (PBS). 
These advantages must be weighed against significant, but 
less well described, disadvantages. These include unregulated 
supply and the potential for:
■ use of expensive medicines when effective and less 
expensive alternatives are available4,6 
■ increased demand for drugs not listed on the PBS
■ issue of expired or poorly stored stock7
■ inability to track or recall the product7
■ medicine issued without a label or accompanying consumer 
medicines information.8
Samples are big business. Marketing expenditure on drug 
samples by American pharmaceutical companies has increased 
annually since 1996, with a total estimated allocation of  
US$10.5 billion in 2001.9  Yet a recent literature review identified 
only 23 papers that had studied the impact of sampling in any 
capacity. The primary focus of these studies was the influence 
of drug samples on prescribing behaviour. Very little has been 
published on the potential adverse outcomes associated with 
samples.10
Consumer calls to the Adverse Medicine 
Events Line
The Adverse Medicine Events Line is a national consumer 
hotline for reporting 'when things go wrong with medicines'. 
This two-year project, funded by the Australian Council for 
Safety and Quality in Health Care and 
operated by Mater Pharmacy Services, 
identified a series of calls from consumers 
where provision of starter packs by doctors 
resulted in either poor quality use of 
medicines or an adverse outcome. The 
motivation for these consumer calls was primarily inadequate 
drug information. None of the samples had been labelled, none 
was accompanied by consumer medicines information or 
simple written instructions regarding dosage, administration, 
indication, storage, possible interactions or adverse effects. The 
nature of these events and the related quality use of medicine 
problems are described in Table 1.
Lack of information 
accompanying starter 
packs can cause medicine 
misadventure
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Table 1
Patient reports of problems involving drug samples given without labelling or written information
Case Problems
1. A 78-year-old male was given a rofecoxib sample  
(25 mg/day). A celecoxib prescription (200 mg/day) was 
given at the next visit. On the third visit, the patient took 
an empty starter pack of rofecoxib and asked for a refill. 
Lack of documentation led to the doctor being unaware 
of the patient using both COX-2 inhibitors for one month. 
Patient was not aware that both medicines were for 
osteoarthritis.
2. A 75-year-old female was given a rofecoxib sample for 
osteoarthritis. She had no recollection of dosage or 
administration with regard to food. 
Anxious patient had failed to initiate the starter pack.  
A previous reaction to an unrelated drug had heightened 
her anxiety.
3. A 66-year-old male was given pravastatin samples. No 
information was provided on dosage or administration 
with regard to food. 
Patient did not commence medicine because of lack 
of counselling. He could not recall being given any 
information.
4. A 50-year-old female was given quetiapine samples. She 
rang to clarify the indication for the new medicine. She 
thought it was for pain relief since her consultation was 
for pain and her previous medicine was celecoxib. 
Patient was unaware that she had been given an 
antipsychotic medicine and intended to commence 
quetiapine 'as required'.
5. A 47-year-old female rang because she had forgotten 
the dose of her new medicine. She had been given one 
month's supply of meloxicam samples at two doses  
(7.5 mg and 15 mg) for osteoarthritis. 
One week treatment delay due to patient's concern with 
regard to lack of directions from the doctor and lack of 
medicines information or label.
6. A 53-year-old female was given a sample of 10 
indapamide tablets.
Patient was unsure if she could drink alcohol with the new 
medicine.
7. A 32-year-old female was given multiple samples of 
fluoxetine (60 mg/day), clonazepam (4 mg/day) and 
quetiapine (200 mg/day). 
Patient took the drugs for three weeks concurrently, before 
questioning how best to take them and what the potential 
adverse effects were.
8. A 50-year-old female was given one month's supply of 
fluoxetine samples for premenstrual tension. 
Patient experienced insomnia, nausea, diarrhoea and 
palpitations and was unaware that these were probably 
drug-induced.
9. A 63-year-old male was given samples of imiquimod 
cream for solar keratosis. 
Patient experienced severe erythematous lesions 48 hours 
later. He was concerned that the lack of consumer medicines 
information delayed him linking the symptoms with the  
new medicine.
10. A 48-year-old female was given a few glyceryl trinitrate 
tablets in a clear plastic specimen container after hospital 
discharge for a suspected heart attack. She was told to 
swallow half a tablet with water for chest pain. 
Possible loss of drug efficacy due to incorrect information 
about its administration and storage. 
11. A 28-year-old male was given four fluvoxamine starter 
packs to 'take the edge off'. 
Patient did not take the drug due to inadequate medicines 
information. Large quantities of starter packs provided.
12. A 39-year-old male was given 80 risperidone tablets  
(2 mg) as samples. 
Dose of half tablet daily equated to 160 days supply.
13. An 89-year-old female was given esomeprazole 40 mg 
samples to take twice daily. Written medicines 
information she obtained from another source gave 
different instructions (40 mg daily, reducing to 20 mg 
daily after one month). She was confused about correct 
dosing. 
Patient did not want to start medicine until correct dose 
was clarified.
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This series of cases shows that lack of information 
accompanying starter packs can cause medicine misadventure, 
specifically:
■ increased patient anxiety
■ treatment delay
■ unintended doubling-up of similar medicines
■ inadvertent use of two strengths of the same medicine
■ inappropriate use due to patient confusion.
In addition, this case series highlighted the fact that some patients 
were being given excessive quantities of a drug. With starter 
packs, there is also an increased potential for medication error 
when the same health professional prescribes, dispenses and 
possibly administers the drug without any checks on the process.
Regulation of starter packs
The provision of starter packs by primary health carers requires 
that medicines be appropriately labelled and accompanied 
by consumer medicines information or equivalent. Failure 
to label starter packs contravenes some state and territory 
legislation. A legislative review11 led to agreement that labelling 
of prescription starter packs will be regulated.1 The feasibility of 
this remains to be determined.
Conclusion
To minimise medicinal misadventure, the drug industry, health 
professionals and consumers need to be aware of the potential 
consequences for the quality use of medicines when starter 
packs are provided.
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Electronically tested
Australian Prescriber was one of the first medical journals in 
the world to make its full text freely available on the internet. 
Many thousands of people visit the website  
(www.australianprescriber.com).
A survey of visitors to the website has confirmed that the 
information is useful to health professionals and the public. 
More than 96% said the information in Australian Prescriber 
was appropriate for their needs. The 'New drugs' section was 
particularly well regarded with 92% of respondents finding the 
commentaries useful.
Among the health professionals, 78% said that their attitudes 
had been influenced by Australian Prescriber and a similar 
number said it had helped them make therapeutic choices. 
People welcomed the free access to the website and said it 
was easy to find what they were looking for. Some people 
prefer the search function, while others use the electronic 
index.
The editorial independence of Australian Prescriber is 
important. More than 95% of participants identified the 
website as a useful resource for independent information on 
drugs and therapeutics. 
Many health professionals still prefer to read their drug 
information on paper. To assess their opinions, the hard copy 
of the journal is currently being evaluated in another survey. 
The results of these surveys will be used to continue the 
development of Australian Prescriber. 
